The study of the specific toxicity of “Apiprost” capsules

Abstract

Introduction. Chronic prostatitis occurs in 35-45% of cases of urological pathology. In recent years there is a tendency to chronic prostatitis increase among young working-age population. This determines the medical and social importance of the problem of improving the effectiveness of treatment of chronic prostatitis. The development of drugs based on bee products and their standardized substances that have a wide range of the pharmacological activity (antimicrobial, antiviral, anti-inflammatory, immunostimulatory, etc.) is of interest for the treatment of prostatitis. One of these drugs is “Apiprost” capsules developed on the basis of apiculture products – bee pollen (BP) and the propolis phenolic hydrophobic drug (PPHD). In preclinical studies “Apiprost” capsules exhibited the marked anti-inflammatory and prostate protective action. The aim of this work was to study some types of specific toxicity of “Apiprost” capsules, namely the presence of immunotoxic, mutagenic action and the ability to cumulate. Materials and Methods. The research was performed according to the guidelines on the preclinical studies of drugs. Results and Discussion. It has been found that “Apiprost” capsules do not reveal the cumulative properties, do not have the mutagenic effect on somatic cells of rats and mice, and do not cause genetic changes in the germ cells of the parent species as evidenced by the absence of death of the first generation offspring at the embryonic stages of development. Conclusions. “Apiprost” capsules in the dose of 100 do not affect the course of the delayed-type hypersensitivity reaction, do not change the number of plasmocytes in the spleen and the titer of hemagglutinins in the blood serum of immunized mice. The increase in the dose to 500 mg / kg has the immunostimulatory effect on the cellular and humoral immunity of animals.